microRNAs as viability biomarkers during Pulsatile Hypothermal Preservation in Renal Transplant Embedding Machine (Q3179343): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): The expression of miRNAs in the preservation solution and blood in a clinical model of suboptimal donors that include donors with expanded criteria or in asystolia, can be biomarkers that allow assessing the viability of the organ during its preservation prior to renal transplantation, identifying the evolution of ischemic renal damage and predicting the development of delayed post-transplant or graft function. Thus, the determination of miRNAs...) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
microRNAs as viability biomarkers during Pulsatile Hypothermal Preservation in Renal Transplant Embedding Machine | |||
Revision as of 19:03, 12 October 2021
Project Q3179343 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | microRNAs as viability biomarkers during Pulsatile Hypothermal Preservation in Renal Transplant Embedding Machine |
Project Q3179343 in Spain |
Statements
30,750.0 Euro
0 references
61,500.0 Euro
0 references
50.0 percent
0 references
1 January 2015
0 references
30 September 2018
0 references
FUNDACION INVESTIGACION BIOMEDICA HOSPITAL RAMON Y CAJAL
0 references
40°25'0.12"N, 3°42'12.89"W
0 references
28079
0 references
La expresión de miRNAs en la solución de preservación y sangre en un modelo clínico de donantes subóptimos que incluyan donantes con criterios expandidos o en asistolia, pueden ser biomarcadores que permitan evaluar la viabilidad del órgano durante su preservación previa al trasplante renal, identificar la evolución del daño renal isquémico y predecir el desarrollo de función retrasada del injerto post-trasplante o de un injerto nunca funcionante. Así, la determinación de miRNAs en líquidos de perfusión podría utilizarse, junto a otros indicadores, como criterio de selección de un injerto renal previo a su trasplante. Adicionalmente la expresión de miRNAs y el conocimiento de los mecanismos moleculares de isquemia-reperfusión podrían tener como resultado la modificación dirigida de la composición de la soluciones de preservación. Para ello proponemos 2 modelos de desarrollo paralelo: Un modelo clínico de trasplante de donantes subóptimos en el que se llevaría a cabo la determinación de miRNAs a lo largo de la secuencia de lesión isquémica y un modelo experimental de auto-trasplante de determinación de biomarcadores de viabilidad durante la preservación hipotérmica en máquina con o sin oxigenación del circuito. Los miRNAs se identificarán mediante arrays de qRT-PCR en suero, se seleccionará una combinación y se validará dicha combinación mediante qRT-PCR individualizadas en una cohorte mayor de individuos (Spanish)
0 references
The expression of miRNAs in the preservation solution and blood in a clinical model of suboptimal donors that include donors with expanded criteria or in asystolia, can be biomarkers that allow assessing the viability of the organ during its preservation prior to renal transplantation, identifying the evolution of ischemic renal damage and predicting the development of delayed post-transplant or graft function. Thus, the determination of miRNAs in infusion fluids could be used, along with other indicators, as a criterion for selecting a renal graft prior to transplantation. Additionally, the expression of miRNAs and the knowledge of the molecular mechanisms of ischemia-reperfusion could result in targeted modification of the composition of preservation solutions. For this we propose 2 parallel development models: A clinical model of suboptimal donor transplantation in which the determination of miRNAs along the sequence of ischemic injury and an experimental model of self-transplantation of determination of viability biomarkers during hypothermal preservation in machine with or without oxygenation of the circuit would be carried out. MiRNAs shall be identified by serum qRT-PCR arrays, a combination selected and the combination validated by individual qRT-PCR in a larger cohort of individuals (English)
12 October 2021
0 references
Madrid
0 references
Identifiers
PI14_01441
0 references